Latest news with #VERVE-102
Yahoo
02-06-2025
- Business
- Yahoo
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on May 30, 2025, the company granted equity awards to four new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received stock options to purchase an aggregate of 65,000 shares of the company's common stock and an aggregate of 22,000 restricted stock units (RSUs). The options have an exercise price of $4.45 per share, which is equal to the closing price of the company's common stock on the date of grant. Each option has a 10-year term and will vest over a period of four years, with 25% of the shares vesting on the one-year anniversary of the grant date and the remainder vesting in equal monthly installments over the following three years, subject to each such employee's continued service with the company on each such vesting date. The RSUs will vest in equal annual installments on the first three anniversaries of July 1, 2025, subject to each such employee's continued service with the company on each such vesting date. About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The company's lead programs –VERVE-102, VERVE-201, and VERVE-301 – target the three cholesterol drivers of atherosclerosis: LDL-C, triglycerides, and Lp(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high LDL-C levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies, and homozygous familial hypercholesterolemia (HoFH). VERVE-301 is designed to permanently turn off the LPA gene to reduce Lp(a) levels. Lp(a) is a genetically validated, independent risk factor for ASCVD, ischemic stroke, thrombosis, and aortic stenosis. For more information, please visit Investor ContactJen RobinsonVerve Therapeutics, Media ContactAshlea Kosikowski1ABashlea@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-04-2025
- Business
- Yahoo
1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street
Equity markets have been volatile this year due to macroeconomic and geopolitical factors. Many of the world's largest corporations haven't escaped the sell-off, and it's hard to predict what's next. Even so, Wall Street has high hopes for some companies. Take Verve Therapeutics (NASDAQ: VERV), a small-cap, clinical-stage biotech. Based on the drugmaker's average price target of $24.43 (according to Yahoo! Finance), the stock could soar by 321% in the next 12 months. That isn't unheard of in the exciting biotech industry, but before rushing to buy Verve Therapeutics' shares, here's what investors need to know about the company. Clinical-stage biotech stocks can experience significant value increases due to promising clinical or regulatory news. If Verve Therapeutics has any chance of soaring by more than 300% in the next year, the company will have to impress the market with its leading candidate, VERVE-102. This product is nowhere close to approval, but can it make enough progress to match the Street's estimates? Notably, Verve Therapeutics recently announced positive results from a Phase 1b clinical trial for VERVE-102 as a potential treatment for heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » HeFH is a genetic disease that causes elevated levels of LDL cholesterol (LDL-C) -- also known as "bad" cholesterol -- which, in high concentration, can lead to severe cardiovascular issues. During the study, a single injection of VERVE-102, an in vivo gene editing therapy, led to a mean LDL-C reduction of 53% in patients. The medicine also showed a reasonable safety profile. These results look promising, especially when considering VERVE-102's potential target market. Verve Therapeutics estimates that there are approximately three million patients in the U.S. and the European Union with HeFH, and 31 million globally. While treatment courses exist, they typically focus on lowering LDL-C levels. VERVE-102, with just one infusion, could address the problem at its source -- a one-time curative option might be a game changer in this area. That said, it will still be a while before VERVE-102 is approved. Verve Therapeutics plans to start phase 2 in the second half of the year. Further, it could still encounter clinical and regulatory setbacks. For all those reasons (and more), Verve Therapeutics' recent clinical success "only" led to a 24% share price increase in one day. Verve Therapeutics is unlikely to see its share price double -- let alone quadruple -- in the next year. There won't be much more significant progress for VERVE-102 in this period, while its other pipeline candidates, which are still in early-stage studies, are unlikely to have a bigger impact on its stock performance than its leading program. Still, that doesn't mean the stock isn't a good investment. Should investors consider adding shares of the gene editing specialist to their portfolios? Like most clinical-stage biotech companies, Verve Therapeutics is far too risky for most investors and isn't worth the trouble, at least not yet. True, it has the backing of a pharmaceutical giant, Eli Lilly, with which it is partnering to develop VERVE-102. That makes it less likely that Verve Therapeutics will run into funding issues -- something that can severely damage a small drugmaker's prospects. It's also true that Verve Therapeutics' approach could set a new standard of care for HeFH and some related cardiovascular diseases. Even so, it will take at least a couple of years before VERVE-102 starts Phase 3 studies, assuming everything goes as expected for the company. If Verve Therapeutics encounters significant headwinds with its leading program, investors could be left with (almost) worthless shares. So, while the stock has considerable upside potential, provided everything goes as planned, there is also ample downside risk. Risk-averse investors should watch this one unfold from the sidelines for now, despite Wall Street's lofty expectations. Before you buy stock in Verve Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Verve Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $594,046!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $680,390!* Now, it's worth noting Stock Advisor's total average return is 872% — a market-crushing outperformance compared to 160% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of April 28, 2025 Prosper Junior Bakiny has positions in Eli Lilly. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. 1 Beaten-Down Stock That Could Skyrocket By 321%, According to Wall Street was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
20-04-2025
- Business
- Yahoo
Why Verve Therapeutics Zoomed 40% Higher This Week
Good news from the laboratory and a clutch of bullish analyst notes were the drivers behind Verve Therapeautics' (NASDAQ: VERV) big stock price leap this week. By the time the dust cleared, the biotech company's shares soared 40% higher over the period, according to data compiled by S&P Global Market Intelligence. Verve is a clinical-stage biotech, so its success depends on how it's progressing with its pipeline. The indications were quite encouraging this week when the company published initial data from a phase 1b clinical trial of VERVE-102, a drug targeting heterozygous familial hypercholesterolemia (HeFH) -- a genetic disorder that causes high cholesterol levels -- and premature coronary artery disease. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » In the trial involving 14 patents, the treatment appeared to be efficacious, particularly in reducing low-density lipoprotein cholesterol (LDL-C) levels in the body. It was also well tolerated with no serious adverse events reported. Following the news, analysts tracking Verve stock wasted little time publishing bullish new notes on the stock. Several raised their price targets with one -- Cantor Fitzgerald -- even upgrading its recommendation to the equivalent of a buy. Not every analyst was so hot on Verve in the wake of the readout; JPMorgan Chase pundit Eric Jospeh actually lowered his price target (to $16 per share from $19). Generally, though, prognosticators greeted the development positively. BMO Capital's Kostas Biliouris, in reiterating his outperform (i.e, buy) recommendation, according to reports wrote in a fresh note that the drug's performance beat expectations, and its safety profile positioned it in "a wide therapeutic window." Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $263,189!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $37,346!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $524,747!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of April 14, 2025 JPMorgan Chase is an advertising partner of Motley Fool Money. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends JPMorgan Chase. The Motley Fool has a disclosure policy. Why Verve Therapeutics Zoomed 40% Higher This Week was originally published by The Motley Fool Sign in to access your portfolio
Globe and Mail
15-04-2025
- Business
- Globe and Mail
Why Verve Therapeutics Is Skyrocketing Today
Verve Therapeutics (NASDAQ: VERV) stock is seeing explosive gains Tuesday. The biotech company's share price was up 24.5% as of 12:30 p.m. ET and had been up as much as 41% earlier in the session. Yesterday, Verve published promising data from its Heart-2 Phase 1b clinical trial of its VERVE-102 treatment for heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease. Several analysts have now raised their price targets on the stock, and investors are buying up shares in response. Verve Therapeutics stock sees a swell of bullish coverage In coverage published this morning, Cantor Fitzgerald raised its rating on Verve Therapeutics stock from neutral to overweight -- indicating that the firm thinks the stock is a good buy. The firm's analysts said that results for VERVE-102 had come in better than expected in terms of both safety and efficacy. Guggenheim also published new coverage on Verve this morning -- maintaining a buy rating on the stock and raising its one-year price target from $18 per share to $24 per share. The firm's analysts cheered on the results for the Heart-2 Phase 1b trial and now sees a 75% chance that the treatment will be successfully marketed -- up from its previous estimate of 60%. Canaccord was even more bullish. The firm reiterated a buy rating on the stock and increased its one-year price target from $32 per share to $39 per share, saying that safety and efficacy results for the treatment in the trial had knocked it out of the park. What's next for Verve Therapeutics? Verve is scheduled to share more information about VERVE-102 at a medical conference this quarter, including trial data from the treatment at a higher dosage level. With the treatment potentially delivering best-in-class results, Verve stock could have room to run above current levels. Should you invest $1,000 in Verve Therapeutics right now? Before you buy stock in Verve Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Verve Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $502,231!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $678,552!* Now, it's worth noting Stock Advisor 's total average return is800% — a market-crushing outperformance compared to156%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of April 14, 2025
Yahoo
15-04-2025
- Business
- Yahoo
Why Verve Therapeutics Is Skyrocketing Today
Verve Therapeutics (NASDAQ: VERV) stock is seeing explosive gains Tuesday. The biotech company's share price was up 24.5% as of 12:30 p.m. ET and had been up as much as 41% earlier in the session. Yesterday, Verve published promising data from its Heart-2 Phase 1b clinical trial of its VERVE-102 treatment for heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease. Several analysts have now raised their price targets on the stock, and investors are buying up shares in response. In coverage published this morning, Cantor Fitzgerald raised its rating on Verve Therapeutics stock from neutral to overweight -- indicating that the firm thinks the stock is a good buy. The firm's analysts said that results for VERVE-102 had come in better than expected in terms of both safety and efficacy. Guggenheim also published new coverage on Verve this morning -- maintaining a buy rating on the stock and raising its one-year price target from $18 per share to $24 per share. The firm's analysts cheered on the results for the Heart-2 Phase 1b trial and now sees a 75% chance that the treatment will be successfully marketed -- up from its previous estimate of 60%. Canaccord was even more bullish. The firm reiterated a buy rating on the stock and increased its one-year price target from $32 per share to $39 per share, saying that safety and efficacy results for the treatment in the trial had knocked it out of the park. Verve is scheduled to share more information about VERVE-102 at a medical conference this quarter, including trial data from the treatment at a higher dosage level. With the treatment potentially delivering best-in-class results, Verve stock could have room to run above current levels. Before you buy stock in Verve Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Verve Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $502,231!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $678,552!* Now, it's worth noting Stock Advisor's total average return is 800% — a market-crushing outperformance compared to 156% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of April 14, 2025 Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Verve Therapeutics Is Skyrocketing Today was originally published by The Motley Fool
